Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：58頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2014’, provides an overview of the Varicella Zoster (HHV-3) Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2014’, provides an overview of the Varicella Zoster (HHV-3) Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Varicella Zoster (HHV-3) Infections Overview 7
Therapeutics Development 8
Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview 8
Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis 9
Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies 10
Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes 12
Varicella Zoster (HHV-3) Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Varicella Zoster (HHV-3) Infections - Products under Development by Companies 16
Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes 17
Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development 18
GlaxoSmithKline plc 18
Novavax, Inc. 19
SK Chemicals Co., Ltd. 20
Nutra Pharma Corporation 21
Green Cross Corporation 22
Beijing Tiantan Biological Products Co., Ltd. 23
Epiphany Biosciences, Inc. 24
Chongqing Zhifei Biological Products Co., Ltd. 25
Varicella Zoster (HHV-3) Infections - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
GSK-208136 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RPI-78M - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
valomaciclovir stearate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Varicella Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MG-1111 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MMR + Varicella Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Varicella Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Varicella Zoster Virus Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Sattabacin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Second Generation Vaccine For VZV Infection - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Varicella Zoster (HHV-3) Infections - Recent Pipeline Updates 50
Varicella Zoster (HHV-3) Infections - Dormant Projects 52
Varicella Zoster (HHV-3) Infections - Discontinued Products 53
Varicella Zoster (HHV-3) Infections - Product Development Milestones 54
Featured News & Press Releases 54
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 54
Jan 28, 2011: Depomed Announces FDA Approval Of GRALISE Once-Daily Tablets For Treatment Of Post-Herpetic Neuralgia 54
Sep 06, 2005: FDA Approves ProQuad, the First and Only Vaccine in the U.S. to Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot. ProQuad Combines Two Well-Established Merck Vaccines, M-M-R II and VARIVAX. 55
Nov 04, 2004: Merck Files Biologics License Application for ProQuad With U.S. Food and Drug Administration. 56
May 13, 2004: ProQuad, Merck's Investigational Combination Vaccine, Resulted in Antibody Responses Similar to Those with M-M-R IIand Varivax in New Study. 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2014 8
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline plc, H1 2014 18
Varicella Zoster (HHV-3) Infections - Pipeline by Novavax, Inc., H1 2014 19
Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H1 2014 20
Varicella Zoster (HHV-3) Infections - Pipeline by Nutra Pharma Corporation, H1 2014 21
Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H1 2014 22
Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 23
Varicella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H1 2014 24
Varicella Zoster (HHV-3) Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Assessment by Combination Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Varicella Zoster (HHV-3) Infections Therapeutics - Recent Pipeline Updates, H1 2014 50
Varicella Zoster (HHV-3) Infections - Dormant Projects, H1 2014 52
Varicella Zoster (HHV-3) Infections - Discontinued Products, H1 2014 53
List of Figures
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2014 8
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Varicella Zoster (HHV-3) Infections Overview 7
Therapeutics Development 8
Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview 8
Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis 9
Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies 10
Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes 12
Varicella Zoster (HHV-3) Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Varicella Zoster (HHV-3) Infections - Products under Development by Companies 16
Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes 17
Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development 18
GlaxoSmithKline plc 18
Novavax, Inc. 19
SK Chemicals Co., Ltd. 20
Nutra Pharma Corporation 21
Green Cross Corporation 22
Beijing Tiantan Biological Products Co., Ltd. 23
Epiphany Biosciences, Inc. 24
Chongqing Zhifei Biological Products Co., Ltd. 25
Varicella Zoster (HHV-3) Infections - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
GSK-208136 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RPI-78M - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
valomaciclovir stearate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Varicella Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MG-1111 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MMR + Varicella Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Varicella Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Varicella Zoster Virus Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Sattabacin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Second Generation Vaccine For VZV Infection - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Varicella Zoster (HHV-3) Infections - Recent Pipeline Updates 50
Varicella Zoster (HHV-3) Infections - Dormant Projects 52
Varicella Zoster (HHV-3) Infections - Discontinued Products 53
Varicella Zoster (HHV-3) Infections - Product Development Milestones 54
Featured News & Press Releases 54
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 54
Jan 28, 2011: Depomed Announces FDA Approval Of GRALISE Once-Daily Tablets For Treatment Of Post-Herpetic Neuralgia 54
Sep 06, 2005: FDA Approves ProQuad, the First and Only Vaccine in the U.S. to Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot. ProQuad Combines Two Well-Established Merck Vaccines, M-M-R II and VARIVAX. 55
Nov 04, 2004: Merck Files Biologics License Application for ProQuad With U.S. Food and Drug Administration. 56
May 13, 2004: ProQuad, Merck's Investigational Combination Vaccine, Resulted in Antibody Responses Similar to Those with M-M-R IIand Varivax in New Study. 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2014 8
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline plc, H1 2014 18
Varicella Zoster (HHV-3) Infections - Pipeline by Novavax, Inc., H1 2014 19
Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H1 2014 20
Varicella Zoster (HHV-3) Infections - Pipeline by Nutra Pharma Corporation, H1 2014 21
Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H1 2014 22
Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 23
Varicella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H1 2014 24
Varicella Zoster (HHV-3) Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Assessment by Combination Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Varicella Zoster (HHV-3) Infections Therapeutics - Recent Pipeline Updates, H1 2014 50
Varicella Zoster (HHV-3) Infections - Dormant Projects, H1 2014 52
Varicella Zoster (HHV-3) Infections - Discontinued Products, H1 2014 53
List of Figures
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2014 8
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
